Time efficacy of a single dose of montelukast on exercise-induced asthma in children.
The aim of this study was to evaluate the timing of onset and the duration of action of a single oral-dose treatment with montelukast in comparison to placebo on exercise-induced asthma (EIA) in asthmatic children. Nineteen children (7-13 years) with stable asthma were evaluated. Patients undertook three consecutive treadmill exercise tests, respectively, 2, 12 and 24 h after a single-dose administration. A double-blind randomized, single-dose, placebo-controlled, crossover design was used. To assess bronchoconstriction after the exercise challenge, the maximal percentage fall in FEV1 (DeltaFEV1) from the baseline value was considered. Two hours after dosing, DeltaFEV1 was -15.33 +/- 2.93 for placebo and -13.33 +/- 2.03 for montelukast. At 12 h, DeltaFEV1 was -18.69 +/- 2.83 for placebo, -9.78 +/- 1.85 for montelukast (p < 0.005). No difference was observed between placebo (DeltaFEV1-10.21 +/- 2.07) and montelukast (DeltaFEV1-9.10 +/- 2.02) at 24 h. Analysis of the degree of protection showed a significant efficacy of montelukast (p = 0.02) in comparison with placebo only at 12 h. Montelukast showed a significant protective effect 12 h after dosing, but no effect after 2 and 24 h. In mild asthmatics, the timing of administration of single dosage before exercise should be strictly considered in order to obtain the drug protective effects.
Peroni
Diego G
DG
Clinica Pediatrica, University of Verona, Italy.
Piacentini
Giorgio L
GL
Ress
Michela
M
Bodini
Alessandro
A
Loiacono
Attilio
A
Aralla
Raffaele
R
Boner
Attilio L
AL
D000085:Acetates / Q000008:administration & dosage*; D000293:Adolescent; D001250:Asthma, Exercise-Induced / Q000188:drug therapy* / Q000503:physiopathology*; D002648:Child; D002669:Child Welfare; D018592:Cross-Over Studies; D003521:Cyclopropanes; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005080:Exercise Test; D005260:Female; D005541:Forced Expiratory Volume / Q000187:drug effects / Q000502:physiology; D006801:Humans; D020024:Leukotriene Antagonists / Q000008:administration & dosage*; D008297:Male; D011804:Quinolines / Q000008:administration & dosage*; D013440:Sulfides; D013997:Time Factors; D016896:Treatment Outcome
D000085:Acetates; D003521:Cyclopropanes; D020024:Leukotriene Antagonists; D011804:Quinolines; D013440:Sulfides; C093875:montelukast